X @Forbes
Forbes·2026-05-02 16:30
Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first FDA approval after 27 years of development. https://t.co/tPZKCxLF8j ...
Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first FDA approval after 27 years of development. https://t.co/tPZKCxLF8j ...